Moderna’s land grab

Can Moderna make the case for mRNA after its record IPO?

A blockbuster IPO by Moderna Inc. (NASDAQ:MRNA) gives the company the opportunity to make the case for mRNA.

With more money, and a broader and more advanced pipeline than other players in the mRNA space, Moderna could establish itself as a leader across several treatment paradigms. But it needs to prove itself with data.

Late Thursday, the company set the record for the largest NASDAQ IPO for a biotech, raising $604.3 million in an upsized offering

Read the full 765 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE